These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 29266809)

  • 21. Impact of the biomarker enrichment strategy in drug development.
    Lara Gongora AB; Carvalho Oliveira LJ; Jardim DL
    Expert Rev Mol Diagn; 2020 Jun; 20(6):611-618. PubMed ID: 31903795
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020.
    Miljkovic MD; Tuia JE; Olivier T; Haslam A; Prasad V
    JAMA Intern Med; 2022 Dec; 182(12):1319-1320. PubMed ID: 36315136
    [TBL] [Abstract][Full Text] [Related]  

  • 23. US Senate passes FDA Revitalization Act.
    Guthrie P
    CMAJ; 2007 Jul; 177(1):23. PubMed ID: 17606930
    [No Abstract]   [Full Text] [Related]  

  • 24. Challenges in evaluating cancer as a clinical outcome in postapproval studies of drug safety.
    Pinheiro SP; Rivera DR; Graham DJ; Freedman AN; Major JM; Penberthy L; Levenson M; Bradley MC; Wong HL; Ouellet-Hellstrom R
    Ann Epidemiol; 2016 Nov; 26(11):735-740. PubMed ID: 27663208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Postmarketing studies for approved human drug and licensed biological products; status reports. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Oct; 65(210):64607-19. PubMed ID: 11503687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. While We're at It, Let's Whack the FDA.
    Chabner BA
    Oncologist; 2016 Mar; 21(3):259-60. PubMed ID: 26869585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recasting cancer trials.
    Nat Biotechnol; 2012 Jul; 30(7):567. PubMed ID: 22781659
    [No Abstract]   [Full Text] [Related]  

  • 28. Oncology update.
    Smart M
    Oncol Nurs Forum; 2011 Jul; 38(4):485-6. PubMed ID: 21708539
    [No Abstract]   [Full Text] [Related]  

  • 29. A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities.
    Lu D; Lu T; Stroh M; Graham RA; Agarwal P; Musib L; Li CC; Lum BL; Joshi A
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):459-76. PubMed ID: 26811176
    [TBL] [Abstract][Full Text] [Related]  

  • 30. This Time I Mean It!
    Tempero M
    J Natl Compr Canc Netw; 2020 Jan; 18(1):1. PubMed ID: 31910382
    [No Abstract]   [Full Text] [Related]  

  • 31. Lessons Learned from Two Decades of Anticancer Drugs.
    Liu Z; Delavan B; Roberts R; Tong W
    Trends Pharmacol Sci; 2017 Oct; 38(10):852-872. PubMed ID: 28709554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The balance of benefit and safety of rosiglitazone: important lessons for our system of drug development and postmarketing assessment.
    Califf RM; Kramer JM
    Pharmacoepidemiol Drug Saf; 2008 Aug; 17(8):782-6. PubMed ID: 18655016
    [No Abstract]   [Full Text] [Related]  

  • 33. A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012-2016).
    Gnanasakthy A; Barrett A; Evans E; D'Alessio D; Romano CD
    Value Health; 2019 Feb; 22(2):203-209. PubMed ID: 30711065
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Roadmap for revitalization?
    Nat Biotechnol; 2007 Oct; 25(10):1061. PubMed ID: 17921973
    [No Abstract]   [Full Text] [Related]  

  • 35. Therapeutic additions and possible deletions in oncology in 2011.
    Holstein SA; Hohl RJ
    Clin Pharmacol Ther; 2012 Jan; 91(1):15-7. PubMed ID: 22179625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anticancer drug development from traditional cytotoxic to targeted therapies: evidence of shorter drug research and development time, and shorter drug lag in Japan.
    Kawabata-Shoda E; Masuda S; Kimura H
    J Clin Pharm Ther; 2012 Oct; 37(5):547-52. PubMed ID: 22428857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The seamless approach to drug development in oncology.
    Pazdur R
    Clin Adv Hematol Oncol; 2016 Dec; 14(12):958-959. PubMed ID: 28212356
    [No Abstract]   [Full Text] [Related]  

  • 38. Reforms on drug safety.
    Nature; 2006 Sep; 443(7110):372. PubMed ID: 17006474
    [No Abstract]   [Full Text] [Related]  

  • 39. US Food and Drug Administration Approval of New Drugs Based on Noninferiority Trials in Oncology: A Dangerous Precedent?
    Gyawali B; Kesselheim AS
    JAMA Oncol; 2019 May; 5(5):607-608. PubMed ID: 30920591
    [No Abstract]   [Full Text] [Related]  

  • 40. US lawmakers tackle safety reforms at the FDA.
    Zwillich T
    Lancet; 2007 Jun; 369(9578):1989-90. PubMed ID: 17577942
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.